BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.